Sartorius Stedim Biotech S.A. (DIM.PA)
EUR 211.5
(2.57%)
EUR 211.5
(2.57%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 309.7 Million EUR | -64.65% |
| 2022 | 876.1 Million EUR | 111.41% |
| 2021 | 414.4 Million EUR | 23.36% |
| 2020 | 335.93 Million EUR | 43.21% |
| 2019 | 234.57 Million EUR | 12.75% |
| 2018 | 208.05 Million EUR | 29.15% |
| 2017 | 161.08 Million EUR | 4.82% |
| 2016 | 153.67 Million EUR | 30.24% |
| 2015 | 117.99 Million EUR | 62.82% |
| 2014 | 72.47 Million EUR | 9.35% |
| 2013 | 66.27 Million EUR | 16.77% |
| 2012 | 56.75 Million EUR | 31.41% |
| 2011 | 43.19 Million EUR | 12.15% |
| 2010 | 38.51 Million EUR | 32.38% |
| 2009 | 29.09 Million EUR | 122.01% |
| 2008 | 13.1 Million EUR | 176.34% |
| 2007 | 4.74 Million EUR | -83.66% |
| 2006 | 29.01 Million EUR | 31.75% |
| 2005 | 22.02 Million EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | 25.5 Million EUR | -46.43% |
| 2024 Q1 | 56 Million EUR | 40.7% |
| 2024 Q2 | 47.6 Million EUR | -15.0% |
| 2023 Q2 | 133.1 Million EUR | 19.8% |
| 2023 Q1 | 111.1 Million EUR | -40.49% |
| 2023 Q4 | 39.8 Million EUR | 54.86% |
| 2023 Q3 | 25.7 Million EUR | -80.69% |
| 2023 FY | 309.7 Million EUR | -64.65% |
| 2022 FY | 876.1 Million EUR | 111.41% |
| 2022 Q4 | 186.7 Million EUR | -6.93% |
| 2022 Q1 | 270.2 Million EUR | 3189.91% |
| 2022 Q2 | 214.8 Million EUR | -20.5% |
| 2022 Q3 | 200.6 Million EUR | -6.61% |
| 2021 FY | 414.4 Million EUR | 23.36% |
| 2021 Q1 | 125.8 Million EUR | 10.11% |
| 2021 Q4 | 8.21 Million EUR | -94.48% |
| 2021 Q3 | 148.8 Million EUR | 0.2% |
| 2021 Q2 | 148.5 Million EUR | 18.04% |
| 2020 FY | 335.93 Million EUR | 43.21% |
| 2020 Q2 | 66.4 Million EUR | -11.11% |
| 2020 Q1 | 74.7 Million EUR | 35.64% |
| 2020 Q4 | 114.24 Million EUR | 14.48% |
| 2020 Q3 | 99.8 Million EUR | 50.3% |
| 2019 Q1 | 56.1 Million EUR | -17.08% |
| 2019 FY | 234.57 Million EUR | 12.75% |
| 2019 Q4 | 55.07 Million EUR | -5.86% |
| 2019 Q3 | 58.5 Million EUR | -9.72% |
| 2019 Q2 | 64.8 Million EUR | 15.51% |
| 2018 Q3 | 49.4 Million EUR | -1.4% |
| 2018 Q2 | 50.1 Million EUR | 22.49% |
| 2018 Q1 | 40.9 Million EUR | -8.88% |
| 2018 Q4 | 67.65 Million EUR | 36.95% |
| 2018 FY | 208.05 Million EUR | 29.15% |
| 2017 Q3 | 37.3 Million EUR | -4.6% |
| 2017 Q4 | 44.88 Million EUR | 20.34% |
| 2017 Q1 | 39.8 Million EUR | 16.11% |
| 2017 FY | 161.08 Million EUR | 4.82% |
| 2017 Q2 | 39.1 Million EUR | -1.76% |
| 2016 Q1 | 36.4 Million EUR | 45.61% |
| 2016 FY | 153.67 Million EUR | 30.24% |
| 2016 Q4 | 34.27 Million EUR | -21.56% |
| 2016 Q3 | 43.7 Million EUR | 11.2% |
| 2016 Q2 | 39.3 Million EUR | 7.97% |
| 2015 FY | 117.99 Million EUR | 62.82% |
| 2015 Q1 | 18.7 Million EUR | 1.4% |
| 2015 Q4 | 24.99 Million EUR | -39.76% |
| 2015 Q3 | 41.5 Million EUR | 26.91% |
| 2015 Q2 | 32.7 Million EUR | 74.87% |
| 2014 Q3 | 19.7 Million EUR | 1.03% |
| 2014 FY | 72.47 Million EUR | 9.35% |
| 2014 Q1 | 15.6 Million EUR | -9.18% |
| 2014 Q2 | 19.5 Million EUR | 25.0% |
| 2014 Q4 | 18.44 Million EUR | -6.39% |
| 2013 Q4 | 17.17 Million EUR | 16.05% |
| 2013 FY | 66.27 Million EUR | 16.77% |
| 2013 Q1 | 13.7 Million EUR | -1.83% |
| 2013 Q2 | 20.6 Million EUR | 50.36% |
| 2013 Q3 | 14.8 Million EUR | -28.16% |
| 2012 Q4 | 13.95 Million EUR | 0.0% |
| 2012 Q2 | 12 Million EUR | 0.0% |
| 2012 FY | 56.75 Million EUR | 31.41% |
| 2011 FY | 43.19 Million EUR | 12.15% |
| 2011 Q2 | 9.5 Million EUR | 0.0% |
| 2010 FY | 38.51 Million EUR | 32.38% |
| 2010 Q2 | 9 Million EUR | 0.0% |
| 2009 Q4 | - EUR | 0.0% |
| 2009 FY | 29.09 Million EUR | 122.01% |
| 2008 FY | 13.1 Million EUR | 176.34% |
| 2007 FY | 4.74 Million EUR | -83.66% |
| 2006 FY | 29.01 Million EUR | 31.75% |
| 2005 FY | 22.02 Million EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Crossject Société Anonyme | -8.63 Million EUR | 3685.321% |
| Safe Orthopaedics SA | -6.96 Million EUR | 4546.518% |
| Spineway SA | -6.51 Million EUR | 4857.296% |
| Amplitude Surgical SA | 1.5 Million EUR | -20546.667% |
| EssilorLuxottica Société anonyme | 2.28 Billion EUR | 86.47% |
| bonyf N.V. | -1.04 Million EUR | 29744.721% |